ALLOVIR INC (ALVR)

US0198181036 - Common Stock

0.7549  -0.01 (-0.87%)

After market: 0.7549 0 (0%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

ALLOVIR INC

NASDAQ:ALVR (3/28/2024, 8:00:00 PM)

After market: 0.7549 0 (0%)

0.7549

-0.01 (-0.87%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap86.10M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

ALVR Daily chart

Company Profile

AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. The company is headquartered in Waltham, Massachusetts and currently employs 106 full-time employees. The company went IPO on 2020-07-30. The firm is engaged in developing allogeneic T-cell therapies to treat and prevent viral diseases. Its virus-specific T cell (VST) therapy platform enables to generate VSTs designed to restore immunity in patients with T cell deficiencies. Its product candidate includes posoleucel, ALVR106, ALVR109, ALVR107 and ALVR108. Its lead product candidate, posoleucel, is a multi- VST therapy targeting six viruses: BK virus (BKV), cytomegalovirus (CMV), adenovirus (AdV), Epstein-Barr virus (EBV), JC virus (JCV), and human herpesvirus 6 (HHV-6). The ALVR106 is an allogeneic VST therapy developed to target diseases caused by four respiratory viruses: respiratory syncytial virus (RSV), influenza, parainfluenza virus (PIV), and human metapneumovirus (hMPV). VST manufacturing platform enables the reproducible generation of single-virus and multi-virus specific cell therapeutic candidates.

Company Info

ALLOVIR INC

1100 Winter Street

Waltham MASSACHUSETTS 02142

P: 16174332605

CEO: David Hallal

Employees: 106

Website: https://www.allovir.com

ALVR News

News Image9 days ago - Pomerantz LLPSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AlloVir, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALVR

/PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against AlloVir, Inc. ("AlloVir" or the "Company") (NASDAQ: ALVR). The class...

News Image10 days ago - Faruqi & Faruqi LLPONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allovir
News Image10 days ago - TheNewswire.comALVR DEADLINE TOMORROW: ROSEN, LEADING INVESTOR COUNSEL, Encourages AlloVir, Inc. Investors to Secure Counsel Before Important March 19 Deadline in Securities Class Action - ALVR

WHY: NEW YORK, NY - (NewMediaWire) - March 18, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of AlloVir, Inc. (NASDAQ: ALVR) between March 22, 2022 and December 21, 2023, both dates inclusive (the “Class Period”), of the important March 19, 2024 lead plaintiff deadline.

News Image10 days ago - NewMediaWireALVR DEADLINE TOMORROW: ROSEN, LEADING INVESTOR COUNSEL, Encourages AlloVir, Inc. Investors to Secure Counsel Before Important March 19 Deadline in Securities Class Action - ALVR

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

News Image10 days ago - InvestorPlaceALVR Stock Earnings: AlloVir Misses EPS for Q4 2023

ALVR stock results show that AlloVir missed analyst estimates for earnings per share the fourth quarter of 2023.

News Image10 days ago - BusinessInsiderALVR Stock Earnings: AlloVir Misses EPS for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips AlloVir (NASDAQ:ALVR) just reported results for the fourth quarter of 2023.Allo...

ALVR Twits

Here you can normally see the latest stock twits on ALVR, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example